PUBLIC COMPANY
save$VNDAVanda Pharmaceuticals Inc.
$VNDA5.3300+1.91%Washington, DC, USupdated 2mo ago
community read0 votes
pipeline
9
marketed
6
phase 3
0
catalysts ytd
2
approvals ytd
1
recalls ytd
0
Pipeline(9)
pipeline depth9 products
2Phase 26Marketed1pre_registration
Marketed
Hetlioz LQ
Circadian Rhythm Sleep Disorders
Marketediloperidone
Bipolar I Disorder
Marketedmilsaperidone
Major Depressive Disorder
Marketedponesimod
Ulcerative Colitis
Sphingosine 1-phosphate receptor 1
Marketedtasimelteon
Circadian Rhythm Sleep Disorders
Marketedtradipitant
Motion Sickness
Phase 2VCA-894A
Charcot-Marie-Tooth Disease Type II
Phase 2VTR-297
Onychomycosis (Tinea Unguium)
pre_registrationimsidolimab
Generalized Pustular Psoriasis (GPP)
IL36 receptor
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- phase3Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
- phase3Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
- phase3Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
- phase3Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
- phase3Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
- phase3A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- phase3Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 22, 26grantDuncan Charles Cliff · director57,101 sh
🐶 Hiring Signal
News
- House passes bill directing FDA to update animal testing rulesThe U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are celebrating the bill as a step toward a new era in preclinical testi…fiercebiotech · 2mo ago
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBraveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is lookin…biospace · 2mo ago
- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksA twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.biopharma_dive · 4mo ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that